Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival-Reference-Cited by-同舟云学术

Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival

Published:2013-08-22 Issue:8 Volume:122 Page:1384-1394
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Burnett Alan K.¹,Russell Nigel H.²,Hunter Ann E.³,Milligan Donald⁴,Knapper Steven⁵,Wheatley Keith⁶,Yin John⁷,McMullin Mary F.⁸,Ali Sahra⁹,Bowen David¹⁰,Hills Robert K.¹

Affiliation:

1. Department of Haematology, Cardiff University School of Medicine, Cardiff, United Kingdom;

2. Department of Haematology, Nottingham University Hospital NHS Trust, Nottingham, United Kingdom;

3. Department of Haematology, Leicester Royal Infirmary, Leicester, United Kingdom;

4. Department of Haematology, Birmingham Heartlands Hospital, Birmingham, United Kingdom;

5. Department of Haematology, University Hospital of Wales, Cardiff, United Kingdom;

6. CRUK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom;

7. Department of Haematology, Manchester Royal Infirmary, Manchester, United Kingdom;

8. Department of Haematology, Belfast City Hospital, Belfast, United Kingdom;

9. Department of Haematology, Castle Hill Hospital, Hull, United Kingdom; and

10. Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Abstract

Key Points In older patients with AML who are not suitable for intensive treatment, clofarabine doubles remission rates Survival is not improved compared with low-dose Ara-C

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/8/1384/1374142/1384.pdf

Reference19 articles.

1. The outcomes and costs of acute myeloid leukemia among the elderly.;Menzin;Arch Intern Med,2002

2. Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival.;Juliusson;Leukemia,2006

3. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.;Juliusson;Blood,2009

4. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly.;Tilly;J Clin Oncol,1990

5. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial.;Burnett;Br J Haematol,2009

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts;Leukemia;2024-01-23

2. Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review;Future Oncology;2023-04

3. Non-intensive acute myeloid leukemia therapies for older patients;Expert Review of Hematology;2023-03-02

4. Acute Myeloid Leukemia Treatment in the Elderly: A Comprehensive Review of the Present and Future;Acta Haematologica;2023

5. Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review;Leukemia & Lymphoma;2022-10-25